UBS: China Life Insurance (02628) new business value growth exceeded expectations. Rating: "Buy"
The line indicates that, as the value of new business has grown strongly this year, China Life holds a more constructive outlook for next year.
UBS released a research report stating that China Life Insurance (02628) saw a 42% increase in new business value in the first nine months, which appears to be better than market expectations; post-tax net profit increased by 61% to 168 billion RMB, in line with earlier profit forecasts. The bank said that with strong growth in new business value this year, China Life has a more constructive outlook for next year. The bank has given the company a "buy" rating with a target price of HK$29.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
